Cargando…

Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a Phase III, 5-day open-label study

OBJECTIVE: We aimed to evaluate the safety and efficacy of a fixed-dose combination (FDC) of tramadol and diclofenac versus a standard approved FDC of tramadol and paracetamol, in patients with acute moderate to severe pain. METHODS: A total of 204 patients with moderate to severe pain due to acute...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandanwale, Ajay S, Sundar, Subramanian, Latchoumibady, Kaliaperumal, Biswas, Swati, Gabhane, Mukesh, Naik, Manoj, Patel, Kamlesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140236/
https://www.ncbi.nlm.nih.gov/pubmed/25152629
http://dx.doi.org/10.2147/JPR.S67817
_version_ 1782331491146006528
author Chandanwale, Ajay S
Sundar, Subramanian
Latchoumibady, Kaliaperumal
Biswas, Swati
Gabhane, Mukesh
Naik, Manoj
Patel, Kamlesh
author_facet Chandanwale, Ajay S
Sundar, Subramanian
Latchoumibady, Kaliaperumal
Biswas, Swati
Gabhane, Mukesh
Naik, Manoj
Patel, Kamlesh
author_sort Chandanwale, Ajay S
collection PubMed
description OBJECTIVE: We aimed to evaluate the safety and efficacy of a fixed-dose combination (FDC) of tramadol and diclofenac versus a standard approved FDC of tramadol and paracetamol, in patients with acute moderate to severe pain. METHODS: A total of 204 patients with moderate to severe pain due to acute musculoskeletal conditions (n=52), acute flare of osteoarthritis (n=52), acute flare of rheumatoid arthritis (n=50), or postoperative pain (n=50) were enrolled in the study at baseline. Each disease category was then randomized to receive either of two treatments for 5 days: group A received an FDC of immediate-release tramadol hydrochloride (50 mg) and sustained-release diclofenac sodium (75 mg) (one tablet, twice daily), and group B received an FDC of tramadol hydrochloride (37.5 mg) and paracetamol (325 mg) (two tablets every 4–6 hours, up to a maximum of eight tablets daily). The primary efficacy end points were reductions in pain intensity from baseline at day 3 and day 5 as assessed by a Visual Analog Scale (VAS) score. RESULTS: Group A showed a significant reduction in the VAS score for overall pain from baseline on day 3 (P=0.001) and day 5 (P<0.0001) as compared with group B. The combination of tramadol-diclofenac resulted in few mild to moderate adverse events (nausea, vomiting, epigastric pain, and gastritis), which required minimal management, without any treatment discontinuation. The number of adverse events in group A was nine (8.82%) compared with 22 (21.78%) in group B, after 5 days of treatment. CONCLUSION: An FDC of tramadol-diclofenac showed a significantly greater reduction in pain intensity and was well tolerated compared with tramadol-paracetamol, resulting in better analgesia in patients suffering from moderate to severe pain due to acute musculoskeletal conditions, postoperative pain following orthopedic surgery, or acute flare of osteoarthritis and rheumatoid arthritis.
format Online
Article
Text
id pubmed-4140236
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-41402362014-08-22 Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a Phase III, 5-day open-label study Chandanwale, Ajay S Sundar, Subramanian Latchoumibady, Kaliaperumal Biswas, Swati Gabhane, Mukesh Naik, Manoj Patel, Kamlesh J Pain Res Original Research OBJECTIVE: We aimed to evaluate the safety and efficacy of a fixed-dose combination (FDC) of tramadol and diclofenac versus a standard approved FDC of tramadol and paracetamol, in patients with acute moderate to severe pain. METHODS: A total of 204 patients with moderate to severe pain due to acute musculoskeletal conditions (n=52), acute flare of osteoarthritis (n=52), acute flare of rheumatoid arthritis (n=50), or postoperative pain (n=50) were enrolled in the study at baseline. Each disease category was then randomized to receive either of two treatments for 5 days: group A received an FDC of immediate-release tramadol hydrochloride (50 mg) and sustained-release diclofenac sodium (75 mg) (one tablet, twice daily), and group B received an FDC of tramadol hydrochloride (37.5 mg) and paracetamol (325 mg) (two tablets every 4–6 hours, up to a maximum of eight tablets daily). The primary efficacy end points were reductions in pain intensity from baseline at day 3 and day 5 as assessed by a Visual Analog Scale (VAS) score. RESULTS: Group A showed a significant reduction in the VAS score for overall pain from baseline on day 3 (P=0.001) and day 5 (P<0.0001) as compared with group B. The combination of tramadol-diclofenac resulted in few mild to moderate adverse events (nausea, vomiting, epigastric pain, and gastritis), which required minimal management, without any treatment discontinuation. The number of adverse events in group A was nine (8.82%) compared with 22 (21.78%) in group B, after 5 days of treatment. CONCLUSION: An FDC of tramadol-diclofenac showed a significantly greater reduction in pain intensity and was well tolerated compared with tramadol-paracetamol, resulting in better analgesia in patients suffering from moderate to severe pain due to acute musculoskeletal conditions, postoperative pain following orthopedic surgery, or acute flare of osteoarthritis and rheumatoid arthritis. Dove Medical Press 2014-08-12 /pmc/articles/PMC4140236/ /pubmed/25152629 http://dx.doi.org/10.2147/JPR.S67817 Text en © 2014 Chandanwale et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Chandanwale, Ajay S
Sundar, Subramanian
Latchoumibady, Kaliaperumal
Biswas, Swati
Gabhane, Mukesh
Naik, Manoj
Patel, Kamlesh
Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a Phase III, 5-day open-label study
title Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a Phase III, 5-day open-label study
title_full Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a Phase III, 5-day open-label study
title_fullStr Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a Phase III, 5-day open-label study
title_full_unstemmed Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a Phase III, 5-day open-label study
title_short Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a Phase III, 5-day open-label study
title_sort efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a phase iii, 5-day open-label study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140236/
https://www.ncbi.nlm.nih.gov/pubmed/25152629
http://dx.doi.org/10.2147/JPR.S67817
work_keys_str_mv AT chandanwaleajays efficacyandsafetyprofileofcombinationoftramadoldiclofenacversustramadolparacetamolinpatientswithacutemusculoskeletalconditionspostoperativepainandacuteflareofosteoarthritisandrheumatoidarthritisaphaseiii5dayopenlabelstudy
AT sundarsubramanian efficacyandsafetyprofileofcombinationoftramadoldiclofenacversustramadolparacetamolinpatientswithacutemusculoskeletalconditionspostoperativepainandacuteflareofosteoarthritisandrheumatoidarthritisaphaseiii5dayopenlabelstudy
AT latchoumibadykaliaperumal efficacyandsafetyprofileofcombinationoftramadoldiclofenacversustramadolparacetamolinpatientswithacutemusculoskeletalconditionspostoperativepainandacuteflareofosteoarthritisandrheumatoidarthritisaphaseiii5dayopenlabelstudy
AT biswasswati efficacyandsafetyprofileofcombinationoftramadoldiclofenacversustramadolparacetamolinpatientswithacutemusculoskeletalconditionspostoperativepainandacuteflareofosteoarthritisandrheumatoidarthritisaphaseiii5dayopenlabelstudy
AT gabhanemukesh efficacyandsafetyprofileofcombinationoftramadoldiclofenacversustramadolparacetamolinpatientswithacutemusculoskeletalconditionspostoperativepainandacuteflareofosteoarthritisandrheumatoidarthritisaphaseiii5dayopenlabelstudy
AT naikmanoj efficacyandsafetyprofileofcombinationoftramadoldiclofenacversustramadolparacetamolinpatientswithacutemusculoskeletalconditionspostoperativepainandacuteflareofosteoarthritisandrheumatoidarthritisaphaseiii5dayopenlabelstudy
AT patelkamlesh efficacyandsafetyprofileofcombinationoftramadoldiclofenacversustramadolparacetamolinpatientswithacutemusculoskeletalconditionspostoperativepainandacuteflareofosteoarthritisandrheumatoidarthritisaphaseiii5dayopenlabelstudy